APD-356 (Arena).

Article Details

Citation
Copy to clipboard

Jandacek RJ

APD-356 (Arena).

Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6.

PubMed ID
16259227 [ View in PubMed
]
Abstract

Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
Lorcaserin5-hydroxytryptamine receptor 2CProteinHumans
Unknown
Not AvailableDetails